Shivani Baliyan
Saturday, March 14, 2026
20
C
Bengaluru
Hot topics
Who Is Monitoring Quality in India’s Small Drug Units?
The Telangana Drugs Control Administration’s stop-use notice on a...
National Seminar on UCPMP
The seminar will help companies especially Product Management Teams and Sales Teams to understand their changing roles due to UCPMP. It will also bring clarity on strategies and promotional inputs including CME's, sampling, gifts etc.
MedicinMan Indian Pharma Digital Adoption Survey
Smaller Indian pharma companies bore the strongest impact from...
First Approach in Pharma
Independence Day Special issue with Vivek Hattangadi tracing the India pharma brand story from before Independence till today.
Why and How Can Pharma Make the Shift from Product Centricity to Customer Centricity?
The customer is the one who buys a product...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
Hot topics
Has Indian Pharma Seen The Longevity Tsunami Coming?
Why India Must Urgently Reinvent Healthcare for a 100-Year...
You can Lead People
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, Soham Wagh and Amit Jain
IQVIAÂ Sponsors Race for 7 to Commemorate World Rare Disease Day
“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."
Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point
In an earlier article in The Wire Science, I...
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Newsletter
Get important news delivered directly to your inbox and stay connected!